Royalty Pharma plc (RPRX)
| Market Cap | 33.91B +60.4% |
| Revenue (ttm) | 2.54B +10.0% |
| Net Income | 811.99M -20.7% |
| EPS | 1.86 -20.0% |
| Shares Out | 575.00M |
| PE Ratio | 31.35 |
| Forward PE | 10.57 |
| Dividend | $0.94 (1.60%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 647,444 |
| Open | 58.27 |
| Previous Close | 58.44 |
| Day's Range | 57.86 - 58.93 |
| 52-Week Range | 34.63 - 64.38 |
| Beta | 0.43 |
| Analysts | Buy |
| Price Target | 65.13 (+10.45%) |
| Earnings Date | Nov 4, 2026 |
About RPRX
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune ... [Read more]
Financial Performance
In 2025, Royalty Pharma's revenue was $2.38 billion, an increase of 5.06% compared to the previous year's $2.26 billion. Earnings were $770.95 million, a decrease of -10.25%.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for RPRX stock is "Buy." The 12-month stock price target is $65.13, which is an increase of 10.45% from the latest price.
News
Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program
NEW YORK and WASHINGTON, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma and Blood Cancer United today announced a $7.5 million donation from Royalty Pharma to support Blood Cancer United's Therapy ...
Royalty Pharma Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Achieved capital deployment targets ahead of schedule, driven by robust deal flow and new opportunities in Big Pharma and China. R&D co-funding and synthetic royalties are expanding, supported by proprietary data and AI capabilities. Innovative deal structures and a strategic push into China are expected to drive long-term growth.
Royalty Pharma to present at upcoming investor conferences
NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September:
Royalty Pharma announces update on Novartis' Phase 3 topline results for pelacarsen
NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an update on Novartis' Phase 3 results from the HORIZON outcomes trial for pelacarsen, an antisense oligo...
Zealand Pharma enters $100M royalty purchase, sale pact with Royalty Pharma
Zealand Pharma (ZLDPF) announced that it has entered into a royalty purchase and sale agreement with Royalty Pharma (RPRX) in exchange for Zealand Pharma’s economics related to rusfertide, a potential...
Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million
NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an agreement for $100 million in funding to Zealand Pharma in exchange for Zealand Pharma's economics rela...
Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide
Company announcement – No. 38 / 2026 Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide Zealand Pharma will re...
Royalty Pharma Slides: Corporate presentation
Royalty Pharma has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.
Royalty Pharma price target raised to $66 from $59 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Royalty Pharma (RPRX) to $66 from $59 and keeps a Buy rating on the shares.
Royalty Pharma price target raised to $65 from $64 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Royalty Pharma (RPRX) to $65 from $64 and keeps an Overweight rating on the shares, noting that the company raised 2026 guidance…
Royalty Pharma price target raised to $70 from $66 at Citi
Citi raised the firm’s price target on Royalty Pharma (RPRX) to $70 from $66 and keeps a Buy rating on the shares. The firm views the company’s Q2 report as…
Royalty Pharma Earnings Call Transcript: Q2 2026
Delivered double-digit growth in Q2 2026, raising full-year guidance as portfolio receipts and royalty receipts exceeded expectations. Expanded development pipeline, deployed $1.1B in royalty acquisitions, and maintained strong returns and financial flexibility.
Royalty Pharma Earnings release: Q2 2026
Royalty Pharma released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Royalty Pharma Slides: Q2 2026
Royalty Pharma has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Royalty Pharma Quarterly report: Q2 2026
Royalty Pharma has published its Q2 2026 quarterly earnings report on August 5, 2026.
Royalty Pharma reports Q2 revenue $647M, consensus $758.88M
“Royalty Pharma (RPRX) delivered strong second quarter results with Royalty Receipts growth of 14%,” said Pablo Legorreta, Royalty Pharma’s Chief Executive Officer and Chairman of the Board. “Our tran...
Royalty Pharma reports second quarter 2026 results
Portfolio Receipts growth of 6% to $773 million; Royalty Receipts growth of 14% Net cash provided by operating activities of $728 million Raised full year 2026 guidance: Portfolio Receipts expected to...
Royalty Pharma appoints Greg Raskin as Senior Vice President, Head of Academic Initiatives
NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Greg Raskin, M.D. as Senior Vice President, Head of Academic Initiatives, effective Aug...
Royalty Pharma buys royalty interest in AstraZeneca cliramitug for $125M upfront
Royalty Pharma (RPRX) announced that it has acquired a portion of Neurimmune’s royalty interest in AstraZeneca’s (AZN) cliramitug for up to $425M, including $125M upfront. Cliramitug is a Phase 3…
Royalty Pharma acquires royalty interest in AstraZeneca's cliramitug for up to $425 million from Neurimmune
NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a portion of Neurimmune's royalty interest in AstraZeneca's cliramitug for up to $425...
Royalty Pharma declares third quarter 2026 dividend
NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2026 of $0.235 per Class A ordin...
Royalty Pharma to announce second quarter 2026 financial results on August 5, 2026
NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2026 financial results on Wednesday, August 5, 2026 before the U.S....
Royalty Pharma price target raised to $65 from $50 at TD Cowen
TD Cowen raised the firm’s price target on Royalty Pharma (RPRX) to $65 from $50 and keeps a Buy rating on the shares. The firm adjusted targets in the pharma…
Royalty Pharma Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The session highlighted the evolution from acquiring traditional royalties to leading in synthetic royalties and R&D funding, with a growing focus on large pharma partnerships and global expansion, especially in China. Recent deals with Revolution Medicines, Novartis, and J&J showcase disciplined, flexible investment strategies.
Royalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conference
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference ...